Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Aid, Alcon, AMarkman, analytical, anemia, ASA, ASC, Attestation, authoritative, Bill, BioPharma, buccal, calcitonin, carefully, Caremark, clarity, Codification, compliant, confirmed, content, CVS, Cyanocobalamin, diligently, distressed, donation, Eckerd, entrepreneurial, escrow, ethyl, Europe, excellence, excise, facilitate, Fenofibrate, fewer, fidaxomicin, finite, Fort, Fraternal, FUL, GxP, Hatch, headcount, Hedging, immaterial, implied, inactive, inception, indemnification, inquiry, intelligent, Interactive, landscape, lapse, Lauderdale, levy, lifecycle, Lodge, Macrobid, marketour, MDRNA, miconozole, modest, mucoadhesive, nasal, Nascobal, Nascobal®Nasal, Nitrofurantoin, noncash, noncredit, nonfinancial, nongovernmental, notable, opined, opposition, Oravig, OravigTM, overhead, Pennsylvania, Police, procure, productsprincipally, Productssegment, Pronova, proportion, proportional, QOL, Raymond, reevaluated, reintroduced, relieve, remeasured, remission, replenishing, resumed, resupply, risperidone, Rite, Rythmol, satisfactory, Scurto, segmentand, seller, Senate, shortage, SKU, soluble, statute, subpoena, system, tangible, TDS, thirteen, travel, travoprost, Tricor, Ultram, Underthe, unexpectedly, unsuccessfully, upper, USP, USPTO, utilizeforecasted, vitamin, Waxman, Zuplenz, ZuplenzTM, ZuplenzTMand, ZuplenzTMin, ZuplenzTMto
Removed:
Abrika, acceleration, Accupril, Addalat, adjusted, advice, Advil, Africa, AG, al, alfuzosin, Ambien, amlodipine, Amoxil, angina, antagonist, APB, Apotex, appetite, arising, assert, assimilation, attempting, attendant, Auerbach, Augmentin, backdated, backdating, bad, benazepril, bloodstream, capitalizing, CC, cefprozil, cephalosporin, Certified, certifying, Clostridum, collaborate, collectibility, collection, communication, condensed, consolidate, construction, copy, covenant, CR, creditable, declare, default, defaulted, derivative, developmental, disclosing, disgorge, Disposal, dropped, EITF, emerging, enforcing, enlarged, enriched, essence, exchanged, exclusively, factual, faith, FAS, feet, fifteen, FIN, fit, formalized, Franklin, frozen, governing, growing, Guaranty, Hariharan, hf, Immtech, infringe, Institute, insured, interpretation, Ivax, label, leading, Leiner, lingual, LLLP, lovastatin, merge, merit, Methylphenidate, Michael, Motrin, nitroglycerin, NitroMist, NitroMistTM, nominal, noninfringement, noted, notification, Nuprin, oncology, outlined, Paxil, pension, permanent, pharmacokinetic, planned, pneumonia, potassium, predetermined, producer, profile, Prozac, purporting, question, quinapril, rated, recommendation, reconfirm, reflecting, relationship, remote, remove, replaced, restate, restructure, resubmit, retroactively, ribavirin, Ritalin, Roxane, seidman, SEPPAA, Shankar, similarly, Somerset, SOP, Southern, SOX, split, Spring, square, stake, stimulant, Supreme, task, thereunder, therewith, Township, trustee, unaware, unjustly, unpaid, unremedied, upheld, Uroxatral, Valley, variable, warehousing, william, wrote, Zolpidem
Filing tables
Filing exhibits
- 10-K Annual report
- 10.6.9 Terms of Restricted Shares Award
- 10.6.10 Terms of Stock Option
- 10.6.11 Terms of Restricted Stock Unit Award
- 10.11.3 Amendment to Lease
- 14 Code of Ethics
- 21 List of Subsidiaries
- 23 Consent of Deloitte & Touche LLP
- 31.1 Certification of Principal Executive Officer
- 31.2 Certification of Principal Executive Officer
- 32.1 Certification of CEO
- 32.2 Certification of CFO
Related press release
PRX similar filings
Filing view
External links
EXHIBIT 23
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement on Form S-3, (No. 333-160115) of our reports dated February 25, 2010 relating to the consolidated financial statements of Par Pharmaceutical Companies, Inc. and subsidiaries, and the effectiveness of Par Pharmaceutical Companies, Inc. and subsidiaries’ internal control over financial reporting appearing in the Annual Report on Form 10-K for the year ended December 31, 2009, and to the reference to us under the heading "Experts" in the Prospectus, which is part of the Registration Statement.
/s/ Deloitte & Touche LLP
Parsippany, NJ
February 25, 2010